On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report examines the impact of PBMs (specifically CVS Caremark, Express Scripts and Optum Rx) on specialty generic drugs, highlighting substantial price markups by PBMs on medications for cancer, HIV and other conditions. The post Healthcare Leaders Support FTC’s…
Three-quarters of U.S. providers and payers say they have increased their IT spending over the past year, according to a new report from Bain & Company and KLAS Research. Both providers and payers are investing in cybersecurity technology, as well as AI tools. The post Providers and Payers Are Increasing Their Tech Spend — Where…
Matthew Eakins, M.D., CEO and co-founder of Atria Health, describes the company’s origins and the market opportunity
As poverty, food insecurity, inadequate housing, and complex comorbidities persist, it is essential that rural healthcare leaders have tools and systems in place to address the health of their neighbors. The post Rural Healthcare Goes Beyond Care: Targeting SDOH to Improve Health Outcomes appeared first on MedCity News.
For decades, the United States has held considerable power in determining the direction of global health policies and programs. President Donald Trump issued three executive orders on his first day in office that may signal the end of that era, health policy experts said. Trump’s order to withdraw from the World Health Organization means the…
Some insurers in the ACA’s small group market are citing tariffs, particularly those affecting prescriptions drugs, as a reason for higher-than-expected premium increases.
The Host Julie Rovner KFF Health News @jrovner Read Julie’s stories. Julie Rovner is chief Washington correspondent and host of KFF Health News’ weekly health policy news podcast, “What the Health?” A noted expert on health policy issues, Julie is the author of the critically praised reference book “Health Care Politics and Policy A to…
Novo Holdings led the Series A investment in Kivu Biosciences, developer of next-generation antibody drug conjugates for solid tumors. The startup’s ADCs and technology were licensed from Synaffix, a Lonza subsidiary. The post Precision Oncology Startup Kivu Unveils $92M for More Stable & Durable ADC Cancer Drugs appeared first on MedCity News.
Galapagos has dropped plans for a business separation that would have enabled the legacy company to focus exclusively on developing new cancer cell therapies. Instead, Galapagos said it will pursue strategic alternatives for its assets. The post Galapagos Says ‘No’ to SpinCo and Instead Will Seek Deals for All Assets appeared first on MedCity News.
For nearly three agonizing years, Mariah Freschi and her husband have been trying to have a second baby. The California mother recently underwent surgery to remove her blocked fallopian tubes, leaving in vitro fertilization as her only option to get pregnant. But the cost quoted by her Sacramento-area clinic was $25,000 — out of reach…